Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma
Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers report.
Materials provided by University of Texas M. D. Anderson Cancer Center. Note: Content may be edited for style and length.
Source link aaaaa